Industry
Biotechnology
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Loading...
Open
57.01
Mkt cap
2.8B
Volume
282K
High
57.64
P/E Ratio
718.38
52-wk high
61.49
Low
55.93
Div yield
N/A
52-wk low
32.31
Portfolio Pulse from
November 11, 2024 | 3:00 pm
Portfolio Pulse from
November 07, 2024 | 7:00 pm
Portfolio Pulse from
November 07, 2024 | 1:15 pm
Portfolio Pulse from Benzinga Newsdesk
August 27, 2024 | 7:06 pm
Portfolio Pulse from Benzinga Insights
August 27, 2024 | 6:00 pm
Portfolio Pulse from Benzinga Newsdesk
August 27, 2024 | 5:13 pm
Portfolio Pulse from Benzinga Newsdesk
August 26, 2024 | 11:47 am
Portfolio Pulse from Benzinga Newsdesk
August 16, 2024 | 8:08 pm
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 8:06 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.